文献速递药物相互作用药物不良反应与药物警戒

精神分裂症患者心血管药物基因组学与认知功能

Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia.
PubMed 文献 · Pharmacotherapy · 2017-08-02

本研究横断面调查122例精神分裂症谱系障碍患者,根据教育年限分为低、中、高认知储备三组。混合模型显示ACE D和APOE ε4携带者语言记忆评分较低,AGT T携带者较高,且仅在低教育组显著;药物-基因交互无显著预测作用。

要点

  • ACE D和APOE ε4携带与低教育组患者语言记忆评分降低相关。
  • AGT T携带与低教育组患者语言记忆评分升高相关。
  • 药物-基因交互作用对BACS评分无显著预测作用。

核心结论

  • 在精神分裂症患者中,ACE D和APOE ε4携带状态与较低语言记忆评分相关,独立于药物使用,且仅在低教育组显著。
  • AGT T携带状态与较高语言记忆评分相关,同样仅在低教育组显著。
  • 药物-基因交互作用不是BACS评分的显著预测因素。

研究设计与样本

  • 横断面研究,在门诊心理健康中心进行。
  • 纳入122例成人精神分裂症谱系诊断患者,且至少6个月前维持稳定抗精神病药方案。
  • 根据正式教育年限分为低教育组(未完成高中或同等学历,18例)、中教育组(完成高中或同等学历,36例)、高教育组(高中后任何学位,68例)。
  • 对AGT M268T(rs699)、ACE I/D(rs1799752)、APOE ε2/ε3/ε4(rs429358和rs7412)进行基因分型。
  • 使用BACS评估认知功能。

主要发现

  • 风险等位基因携带状态在各认知储备组间无显著差异。
  • 高血压、高脂血症诊断及降压药、降脂药使用在各认知储备组间无显著差异。
  • 混合模型显示ACE D携带与较低语言记忆评分相关(p=0.0055)。
  • APOE ε4携带与较低语言记忆评分相关(p=0.0188)。
  • AGT T携带与较高语言记忆评分相关(p=0.0058)。

临床怎么用

  • 对精神分裂症患者,尤其低教育水平者,可考虑ACE D和APOE ε4基因型评估语言记忆损害风险。
  • AGT T携带状态可能与较好语言记忆相关,但需进一步验证。
  • 提高认知储备(如教育)可能减轻心血管风险等位基因对认知的负面影响。
  • 药物使用未显著改变基因型与认知的关联,但需注意样本量限制。

局限性

  • 横断面设计无法推断因果关系。
  • 样本量较小(122例),低教育组仅18例。
  • 仅评估语言记忆等认知维度,未全面覆盖认知功能。
  • 未报告其他潜在混杂因素如病程、症状严重程度等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The authors sought to examine the impact of multiple risk alleles for cognitive dysfunction and cardiovascular disease risk on cognitive function and to determine if these relationships varied by cognitive reserve (CR) or concomitant medication use in patients with schizophrenia. They conducted a cross-sectional study in ambulatory mental health centers. A total of 122 adults with a schizophrenia spectrum diagnosis who were maintained on a stable antipsychotic regimen for at least 6 months before study enrollment were included. Patients were divided into three CR groups based on years of formal education: no high school completion or equivalent (low-education group [18 patients]), completion of high school or equivalent (moderate-education group [36 patients], or any degree of post-high school education (high-education group [68 patients]). The following pharmacogenomic variants were genotyped for each patient: AGT M268T (rs699), ACE insertion/deletion (or ACE I/D, rs1799752), and APOE ε2, ε3, and ε4 (rs429358 and rs7412). Risk allele carrier status (identified per gene as AGT M268 T carriers, ACE D carriers, and APOE ε4 carriers) was not significantly different among CR groups. The Brief Assessment of Cognition in Schizophrenia (BACS) scale was used to assess cognitive function. The mean ± SD patient age was 43.9 ± 11.6 years. Cardiovascular risk factors such as hypertension and hyperlipidemia diagnoses, and use of antihypertensive and lipid-lowering agents, did not significantly differ among CR groups. Mixed modeling revealed that risk allele carrier status was significantly associated with lower verbal memory scores for ACE D and APOE ε4 carriers, but AGT T carrier status was significantly associated with higher verbal memory scores (p=0.0188, p=0.0055, and p=0.0058, respectively). These results were only significant in the low-education group. In addition, medication-gene interactions were not significant predictors of BACS scores. ACE D and APOE ε4 carrier status, independent of medication use, was associated with lower verbal memory scores in patients with schizophrenia who had relatively lower CR, as identified by formal education. These results suggest that increasing CR may be protective against cognitive impairment that may be worsened by select cardiovascular risk alleles in patients with schizophrenia.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Ward KM, Kraal AZ, Flowers SA, et al. Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia. Pharmacotherapy. 2017. PMID: 28605058. doi:10.1002/phar.1968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。